Hyperphosphatemia is a condition that means you have high levels of phosphorus in your body. It can happen due to your diet or a change in your kidneys’ function. Often, hyperphosphatemia has no ...

New York, June 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hyperphosphatemia Treatment Global Market Report 2022" - https://www ...

Please provide your email address to receive an email when new articles are posted on . Low-dose sevelamer in combination with a calcium-based phosphorus binder may be used in resource-constrained ...

Please provide your email address to receive an email when new articles are posted on . Phase 3 results from the PHREEDOM study demonstrated treatment with tenapanor safely and effectively decreased ...

Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially ...

DUBAI, United Arab Emirates, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Future Market Insights estimates that the Hyperphosphatemia Market will experience a rapid expansion between the years 2023 and 2033. By ...

Credit: Ardelyx. Xphozah is a first-in-class oral medication designed to block sodium/hydrogen exchange 3 in the GI tract. Xphozah ® (tenapanor) is now available to reduce serum phosphorus in adults ...

Investigators ruled out hyperphosphatemia and SHPT as confounders in each other's association with CKD outcomes. Secondary hyperparathyroidism (SHPT) is associated with progression of chronic kidney ...

Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...

Diabetes, COPD Raise Post-Kidney Transplant Readmission Rates High phosphate levels are associated with 3.3-fold increased odds of 28-day in-hospital mortality. Hyperphosphatemia predicts an increased ...

As a physician and researcher caring for people with chronic kidney disease, I see firsthand the challenges that patients undergoing dialysis face. Dialysis is life-sustaining, but it also brings ...

Due to the lack of an appropriate dosage strength, Velphoro is not approved in pediatric patients 6 years to less than 9 years of age. The Food and Drug Administration (FDA) has expanded the approval ...